Superworth

Amgen AMGN

Drug Manufacturers - General, Healthcare
$466.72
+0.27%
Market cap
$252.3B
PE
29.0×
10y median 21.2×
Forward PE
19.8×
10y median 14.5×
Price to sales
6.6×
EV/EBIT
25.8×
Revenue, 12 months
$38.1B
+9% on a year ago
Net margin
23.0%
Free cash flow yield
4.0%

Amgen trades at 29.0× trailing earnings, pricier than 80% of the last ten years. Revenue was $38.1B over the last twelve months, up 9% on a year earlier with a 23% net margin.

Charts

Financials

Income statement for AMGN, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$6.9B+4%$8.2B+20%$7.4B+22%$8.4B+20%$8.5B+23%$9.1B+11%$8.1B+9%$9.2B+9%$9.6B+12%$9.9B+9%$8.6B+6%$10.1B+10%
Cost of revenue$1.8B+14%$3.1B+78%$3.2B+86%$3.2B+79%$3.3B+83%$3.1B+0%$3B−7%$3B−7%$3.1B−7%$3B−4%$2.7B−8%$2.8B−7%
Gross profit$5.1B+1%$5.1B−0%$4.2B−3%$5.2B−0%$5.2B+2%$6B+18%$5.2B+22%$6.2B+20%$6.5B+25%$6.9B+15%$5.9B+13%$7.2B+17%
R&D$1.1B−3%$1.5B+16%$1.3B+27%$1.4B+30%$1.4B+34%$1.7B+12%$1.5B+11%$1.7B+21%$1.9B+31%$2.1B+24%$1.7B+16%$1.9B+7%
SG&A$1.4B+5%$2.3B+45%$1.8B+44%$1.8B+38%$1.6B+20%$1.9B−17%$1.7B−7%$1.7B−5%$1.7B+6%$2B+4%$1.6B−5%$1.7B+3%
$2B−24%$1.3B−43%$991M−48%$1.9B−29%$2B+1%$2.3B+82%$1.2B+19%$2.7B+39%$2.5B+23%$2.7B+18%$2.7B+126%$3.5B+32%
Interest expense$759M+106%$821M+98%$824M+52%$808M+7%$776M+2%$747M−9%$723M−12%$694M−14%$685M−12%$653M−13%$657M−9%$673M−3%
Pre-tax income$1.9B−19%$852M−51%−$68M$794M−51%$3.1B+59%$782M−8%$2B$1.6B+98%$3.9B+26%$1.5B+94%$2.1B+6%$2.8B+77%
$217M−13%$85M−36%$45M−93%$48M−80%$271M+25%$155M+82%$243M+440%$136M+183%$705M+160%$181M+17%$265M+9%$393M+189%
Net income$1.7B−19%$767M−53%−$113M$746M−46%$2.8B+64%$627M−18%$1.7B$1.4B+92%$3.2B+14%$1.3B+113%$1.8B+5%$2.4B+66%
$3.22−19%$1.42−53%−$0.21$1.38−46%$5.22+62%$1.16−18%$3.20$2.65+92%$5.93+14%$2.45+111%$3.34+4%$4.37+65%
538M+0%540M+0%536M−0%541M+1%542M+1%542M+0%541M+1%541M+0%542M+0%543M+0%544M+1%544M+1%

Gross profit: 73 periods, Q2 FY08 to Q2 FY26: not printed by the filing, worked out from its own lines.

Net income: 6 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.

EPS, diluted: Q4 FY08: quarter's net income to common over its shares, to the cent. 6 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.

Diluted shares: 11 periods, Q4 FY08 to Q4 FY20: share-days: the 12-month average less the 9-month, weighted by days. 6 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release. Q4 FY17: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet. Figures from older filings without data tags, and from a results release before its 10-Q, are read from the document's text and checked against it.

Estimates

Next earnings report: .

QuarterRevenueRangeEPSRangeAnalysts
Q3 FY26$10.1B$9.9B to $10.2B$5.79$5.55 to $6.0919
Q4 FY26$10.3B$10.1B to $10.5B$5.79$5.24 to $6.0917
Q1 FY27$9.4B$9.1B to $9.6B$5.62$5.42 to $5.787
Q2 FY27$10.3B$10.1B to $10.6B$6.41$6.18 to $6.6015
Q3 FY27$10.3B$10B to $10.5B$6.32$6.10 to $6.509
Q4 FY27$10.5B$10.2B to $10.7B$6.28$6.05 to $6.457
Q1 FY28$9.5B$9.2B to $9.7B$5.86$5.65 to $6.039
Q2 FY28$10.3B$10B to $10.6B$6.68$6.44 to $6.878

Peers

Companies in Drug Manufacturers - General nearest Amgen's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
AMGNAmgen$252.3B29.0×21.2×19.8×6.6×+9%23.0%
GILDGilead Sciences$212.5Bn/m18.8×19.8×6.9×+7%−12.5%
PFEPfizer$176B40.6×15.8×11.2×2.8×−0%6.8%
MRKMerck$359.5B150×25.0×17.2×5.3×+5%3.6%
BMYBristol-Myers Squibb$128.7B14.0×19.9×9.8×2.6×+4%18.5%
ABBVAbbVie$511.6B49.8×27.9×18.3×7.7×+11%15.7%
JNJJohnson & Johnson$650.2B40.9×24.3×23.9×6.5×+8%n/m
LLYEli Lilly and$1.3T46.5×41.6×30.9×15.6×+46%31.9%
BIIBBiogen$37B44.3×16.2×19.0×3.7×+0%8.3%
Peer median$286B44.3×22.1×18.7×5.9×+6%8.3%

More on Amgen

Each number over time

Where it ranks

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .